Clinical Microbiology Reviews最新文献_第8页

Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management. 真菌性心内膜炎：病理生理学，流行病学，临床表现，诊断和管理。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2023-09-21 Epub Date: 2023-07-13 DOI: 10.1128/cmr.00019-23

George R Thompson, Jeffrey D Jenks, John W Baddley, James S Lewis, Matthias Egger, Ilan S Schwartz, Johannes Boyer, Thomas F Patterson, Sharon C-A Chen, Peter G Pappas, Martin Hoenigl

{"title":"Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.","authors":"George R Thompson, Jeffrey D Jenks, John W Baddley, James S Lewis, Matthias Egger, Ilan S Schwartz, Johannes Boyer, Thomas F Patterson, Sharon C-A Chen, Peter G Pappas, Martin Hoenigl","doi":"10.1128/cmr.00019-23","DOIUrl":"10.1128/cmr.00019-23","url":null,"abstract":"Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated with high morbidity and mortality (>70%), and presents numerous challenges during clinical care. Candida spp. are the most common causes of fungal endocarditis, implicated in over 50% of cases, followed by Aspergillus and Histoplasma spp. Important risk factors for fungal endocarditis include prosthetic valves, prior heart surgery, and injection drug use. The signs and symptoms of fungal endocarditis are nonspecific, and a high degree of clinical suspicion coupled with the judicious use of diagnostic tests is required for diagnosis. In addition to microbiological diagnostics (e.g., blood culture for Candida spp. or galactomannan testing and PCR for Aspergillus spp.), echocardiography remains critical for evaluation of potential infective endocarditis, although radionuclide imaging modalities such as 18F-fluorodeoxyglucose positron emission tomography/computed tomography are increasingly being used. A multimodal treatment approach is necessary: surgery is usually required and should be accompanied by long-term systemic antifungal therapy, such as echinocandin therapy for Candida endocarditis or voriconazole therapy for Aspergillus endocarditis.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":" ","pages":"e0001923"},"PeriodicalIF":19.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10132286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations. 支气管败血博德菌和百日咳博德菌：感染、免疫调节和疫苗注意事项的异同。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2023-09-21 Epub Date: 2023-06-12 DOI: 10.1128/cmr.00164-22

Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Stéphanie Longet, Egbert Mundt, Stéphane Paul

{"title":"Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations.","authors":"Beatriz Miguelena Chamorro, Karelle De Luca, Gokul Swaminathan, Stéphanie Longet, Egbert Mundt, Stéphane Paul","doi":"10.1128/cmr.00164-22","DOIUrl":"10.1128/cmr.00164-22","url":null,"abstract":"Bordetella pertussis and Bordetella bronchiseptica belong to the genus Bordetella, which comprises 14 other species. B. pertussis is responsible for whooping cough in humans, a severe infection in children and less severe or chronic in adults. These infections are restricted to humans and currently increasing worldwide. B. bronchiseptica is involved in diverse respiratory infections in a wide range of mammals. For instance, the canine infectious respiratory disease complex (CIRDC), characterized by a chronic cough in dogs. At the same time, it is increasingly implicated in human infections, while remaining an important pathogen in the veterinary field. Both Bordetella can evade and modulate host immune responses to support their persistence, although it is more pronounced in B. bronchiseptica infection. The protective immune responses elicited by both pathogens are comparable, while there are important characteristics in the mechanisms that differ. However, B. pertussis pathogenesis is more difficult to decipher in animal models than those of B. bronchiseptica because of its restriction to humans. Nevertheless, the licensed vaccines for each Bordetella are different in terms of formulation, route of administration and immune responses induced, with no known cross-reaction between them. Moreover, the target of the mucosal tissues and the induction of long-lasting cellular and humoral responses are required to control and eliminate Bordetella. In addition, the interaction between both veterinary and human fields are essential for the control of this genus, by preventing the infections in animals and the subsequent zoonotic transmission to humans.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":" ","pages":"e0016422"},"PeriodicalIF":36.8,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9668006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum for Nyaruaba et al., "Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks". Nyaruaba等人的勘误，“数字PCR在SARS-CoV-2/COVID-19时代的应用:未来疫情的路线图”。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2023-06-21 DOI: 10.1128/cmr.00052-23

Raphael Nyaruaba, Caroline Mwaliko, David Dobnik, Pavel Neužil, Patrick Amoth, Matilu Mwau, Junping Yu, Hang Yang, Hongping Wei

引用次数: 0

Congenital Syphilis: a Review of Global Epidemiology. 先天性梅毒：全球流行病学回顾。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2023-06-21 Epub Date: 2023-03-15 DOI: 10.1128/cmr.00126-22

Leeyan S Gilmour, Tony Walls

引用次数: 0

Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections. 治疗耐万古霉素肠球菌血流感染的药物。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2023-06-21 Epub Date: 2023-04-17 DOI: 10.1128/cmr.00059-22

Kelly A Cairns, Andrew A Udy, Trisha N Peel, Iain J Abbott, Michael J Dooley, Anton Y Peleg

引用次数: 0

Host Immunity and Immunization Strategies for Clostridioides difficile Infection. 艰难梭菌感染的宿主免疫和免疫策略。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2023-06-21 Epub Date: 2023-05-10 DOI: 10.1128/cmr.00157-22

Farha Naz, William A Petri

引用次数: 0

An Overlooked and Underrated Endemic Mycosis-Talaromycosis and the Pathogenic Fungus Talaromyces marneffei. 被忽视和低估的地方性真菌病--马拉色菌病和致病真菌马拉色菌（Talaromyces marneffei）。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2023-03-23 Epub Date: 2023-01-17 DOI: 10.1128/cmr.00051-22

Fang Wang, RunHua Han, Shi Chen

{"title":"An Overlooked and Underrated Endemic Mycosis-Talaromycosis and the Pathogenic Fungus Talaromyces marneffei.","authors":"Fang Wang, RunHua Han, Shi Chen","doi":"10.1128/cmr.00051-22","DOIUrl":"10.1128/cmr.00051-22","url":null,"abstract":"Talaromycosis is an invasive mycosis endemic in tropical and subtropical Asia and is caused by the pathogenic fungus Talaromyces marneffei. Approximately 17,300 cases of T. marneffei infection are diagnosed annually, and the reported mortality rate is extremely high (~1/3). Despite the devastating impact of talaromycosis on immunocompromised individuals, particularly HIV-positive persons, and the increase in reported occurrences in HIV-uninfected persons, diagnostic and therapeutic approaches for talaromycosis have received far too little attention worldwide. In 2021, scientists living in countries where talaromycosis is endemic raised a global demand for it to be recognized as a neglected tropical disease. Therefore, T. marneffei and the infectious disease induced by this fungus must be treated with concern. T. marneffei is a thermally dimorphic saprophytic fungus with a complicated mycological growth process that may produce various cell types in its life cycle, including conidia, hyphae, and yeast, all of which are associated with its pathogenicity. However, understanding of the pathogenic mechanism of T. marneffei has been limited until recently. To achieve a holistic view of T. marneffei and talaromycosis, the current knowledge about talaromycosis and research breakthroughs regarding T. marneffei growth biology are discussed in this review, along with the interaction of the fungus with environmental stimuli and the host immune response to fungal infection. Importantly, the future research directions required for understanding this serious infection and its causative pathogenic fungus are also emphasized to identify solutions that will alleviate the suffering of susceptible individuals worldwide.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":"36 1","pages":"e0005122"},"PeriodicalIF":36.8,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9579992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections. mRNA 疫苗技术时代与寄生虫感染的未来控制。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2023-03-23 Epub Date: 2023-01-10 DOI: 10.1128/cmr.00241-21

Hong You, Malcolm K Jones, Catherine A Gordon, Alexa E Arganda, Pengfei Cai, Harry Al-Wassiti, Colin W Pouton, Donald P McManus

{"title":"The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.","authors":"Hong You, Malcolm K Jones, Catherine A Gordon, Alexa E Arganda, Pengfei Cai, Harry Al-Wassiti, Colin W Pouton, Donald P McManus","doi":"10.1128/cmr.00241-21","DOIUrl":"10.1128/cmr.00241-21","url":null,"abstract":"Despite intensive long-term efforts, with very few exceptions, the development of effective vaccines against parasitic infections has presented considerable challenges, given the complexity of parasite life cycles, the interplay between parasites and their hosts, and their capacity to escape the host immune system and to regulate host immune responses. For many parasitic diseases, conventional vaccine platforms have generally proven ill suited, considering the complex manufacturing processes involved and the costs they incur, the inability to posttranslationally modify cloned target antigens, and the absence of long-lasting protective immunity induced by these antigens. An effective antiparasite vaccine platform is required to assess the effectiveness of novel vaccine candidates at high throughput. By exploiting the approach that has recently been used successfully to produce highly protective COVID mRNA vaccines, we anticipate a new wave of research to advance the use of mRNA vaccines to prevent parasitic infections in the near future. This article considers the characteristics that are required to develop a potent antiparasite vaccine and provides a conceptual foundation to promote the development of parasite mRNA-based vaccines. We review the recent advances and challenges encountered in developing antiparasite vaccines and evaluate the potential of developing mRNA vaccines against parasites, including those causing diseases such as malaria and schistosomiasis, against which vaccines are currently suboptimal or not yet available.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":"36 1","pages":"e0024121"},"PeriodicalIF":19.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9944172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiviral Approaches against Influenza Virus. 针对流感病毒的抗病毒方法。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2023-03-23 Epub Date: 2023-01-16 DOI: 10.1128/cmr.00040-22

Rashmi Kumari, Suresh D Sharma, Amrita Kumar, Zachary Ende, Margarita Mishina, Yuanyuan Wang, Zackary Falls, Ram Samudrala, Jan Pohl, Paul R Knight, Suryaprakash Sambhara

{"title":"Antiviral Approaches against Influenza Virus.","authors":"Rashmi Kumari, Suresh D Sharma, Amrita Kumar, Zachary Ende, Margarita Mishina, Yuanyuan Wang, Zackary Falls, Ram Samudrala, Jan Pohl, Paul R Knight, Suryaprakash Sambhara","doi":"10.1128/cmr.00040-22","DOIUrl":"10.1128/cmr.00040-22","url":null,"abstract":"Preventing and controlling influenza virus infection remains a global public health challenge, as it causes seasonal epidemics to unexpected pandemics. These infections are responsible for high morbidity, mortality, and substantial economic impact. Vaccines are the prophylaxis mainstay in the fight against influenza. However, vaccination fails to confer complete protection due to inadequate vaccination coverages, vaccine shortages, and mismatches with circulating strains. Antivirals represent an important prophylactic and therapeutic measure to reduce influenza-associated morbidity and mortality, particularly in high-risk populations. Here, we review current FDA-approved influenza antivirals with their mechanisms of action, and different viral- and host-directed influenza antiviral approaches, including immunomodulatory interventions in clinical development. Furthermore, we also illustrate the potential utility of machine learning in developing next-generation antivirals against influenza.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":"36 1","pages":"e0004022"},"PeriodicalIF":19.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human Listeriosis. 人类李斯特菌病

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2023-03-23 Epub Date: 2022-12-08 DOI: 10.1128/cmr.00060-19

Merel M Koopmans, Matthijs C Brouwer, José A Vázquez-Boland, Diederik van de Beek

引用次数: 15